Search
Dasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigational[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. … [A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region
Synonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexCopanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalPI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. … Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDETislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses. … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsIdecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma. … Multiple myeloma is a cancer where plasma cells rapidly divide out of control.
Desloratadine
go.drugbank.com/drugs/DB00967ApprovedInvestigationalIt is the active descarboethoxy metabolite of loratidine (a second generation histamine). … Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action.
Products: URTISIN LAM, DESLORATADIN 1A PHAR 5MGButenafine
go.drugbank.com/drugs/DB01091ApprovedButenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. … In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.
Synonyms: N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine, (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamineProducts: Tinactin Once-A-day CreamSerdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma … [A230698, A230703] The underlying cause of ADHD is unclear but likely involves dysfunction in dopaminergic and noradrenergic neurotransmission, as evidenced by the clear beneficial effect of CNS stimulants
Latamoxef
go.drugbank.com/drugs/DB04570ApprovedLatamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Olmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalIn particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. … ARBs such as olmesartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression
Mixtures: OLMEDOXTAN A®, OLMESAR/AMLOD AL 20/5MGCategories: Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs), plain